IDH1 or IDH2 mutations have been identified in more than 70% of CNS neoplasms diagnosed as grade II and III astrocytoma, oligodendroglioma, oligoastrocytoma, and secondary glioblastoma. Here, IDH2 is linked to central nervous system neoplasm.